The influence of some antipsychotics on erythrocyte magnesium and plasma magnesium, calcium, copper and zinc in patients with paranoid schizophrenia.

What Was Tested

The paper reports a study of Antipsychotic Agents, published as a randomized controlled trial.

The aim of the study was the investigation of plasma magnesium, calcium, copper and zinc and erythrocyte magnesium levels in patients with paranoid schizophrenia and the influence of the therapy with two antipsychotic drugs (haloperidol and risperidone) on these concentrations.

Who Took Part

The study group was 56 patients.

By PubMed's age tags, the people studied were teenagers, adults, middle-aged adults and older adults, both men and women.

The researchers investigated the influence of treatment with haloperidol and risperidoneon plasma and erythrocyte magnesium and on plasmatic levels of zinc, calcium and copper on hospitalized 56 patients diagnosed with paranoid schizophrenia (DSM IV).

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Antipsychotic Agents study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

Topics PubMed links to this paper include Antipsychotic Agents, Biomarkers, Calcium, Copper, Erythrocytes, Haloperidol and Magnesium.

What This Means in Plain Language

The paper is a randomized study of Antipsychotic Agents in 56 patients.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2004 (Journal of the American College of Nutrition), a journal based in United States.

More context: all human trials.